Results from plasmaMATCH trial treatment cohort A: A phase II trial of extended-dose fulvestrant in patients with an ESR1 mutation identified via ctDNA screening (CRUK/15/010)

被引：3

作者：

Macpherson, Iain ^{[1
]}

Kilburn, Lucy ^{[2
]}

Kernaghan, Sarah ^{[2
]}

Wardley, Andrew M. ^{[3
,4
]}

Baird, Richard D. ^{[5
]}

Roylance, Rebecca ^{[6
,7
]}

Stephens, Peter ^{[8
]}

Oikonomidou, Olga ^{[9
]}

Braybrooke, Jeremy P. ^{[10
]}

Tuthill, Mark ^{[11
]}

Abraham, Jacinta ^{[12
]}

Winter, Matthew C. ^{[13
]}

Kingston, Belinda ^{[14
]}

Wilkinson, Katie ^{[2
]}

Ring, Alistair ^{[15
]}

Bliss, Judith M. ^{[2
]}

Turner, Nicholas ^{[14
,15
]}

机构：

[1] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[2] Inst Canc Res, Clin Trials & Stat Unit, London, England

[3] Christie NHS Fdn Trust, NIHR Manchester Clin Res Facil, Manchester, Lancs, England

[4] Fac Biol, Sch Med Sci, Div Canc Sci, Manchester, Lancs, England

[5] Canc Res UK Cambridge Ctr, Cambridge, England

[6] Univ Coll London Hosp NHS Fdn Trust, London, England

[7] NIHR Univ Coll London Hosp Biomed Res Ctr, London, England

[8] Royal Devon & Exeter NHS Fdn Trust, Exeter, Devon, England

[9] Western Gen Hosp, Edinburgh Canc Ctr, Edinburgh, Midlothian, Scotland

[10] Univ Hosp Bristol NHS Fdn Trust, Bristol, Avon, England

[11] Oxford Univ Hosp NHS Fdn Trust, Oxford, England

[12] Velindre Univ NHS Trust, Cardiff, Wales

[13] Sheffield Teaching Hosp NHS Fdn Trust, Weston Pk Hosp, Sheffield, S Yorkshire, England

[14] Inst Canc Res, London, England

[15] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England

来源：

关键词：

D O I：

10.1158/1538-7445.SABCS19-P1-19-04

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1-19-04

引用

页数：3